Coronary disease & ACSCohort study

Late Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention in the Workup Pre-TAVR

JACC Cardiovasc IntervPublished

  • Multicentre cohort study
  • consecutive patients

Authors' conclusion

In TAVR candidates with concomitant significant coronary artery disease requiring percutaneous treatment, LBEs after TAVR were frequent and associated with increased mortality. Combining antiplatelet and anticoagulation regimens and the occurrence of periprocedural bleeding determined an increased risk of LBEs.

Study context

Population
Patients undergoing percutaneous coronary intervention (PCI) in the work-up pre-TAVR who underwent TAVR and survived beyond 30 days (mean age 81 ± 7 years; 41.5% women)
Participants
1,457 consecutive patients
Exposure
Late bleeding events (LBEs) vs no bleeding
  • LBEsn = 116
Outcome
Incidence, characteristics, associated factors and outcomes of LBEs

Main finding

As reported in the abstract

Incidence of LBEs · median follow-up 23 (IQR: 12-40) months
GroupValueMinorMajorLife-threatening or disabling
LBEs7.9%21 (18.1%)63 (54.3%)32 (27.6%)

Observational data: associations, not effects.

Further findings

OutcomeLBEsNo bleedingP value
Mortality · 4-year follow-up43.9%36.0P = 0.034

Severity of late bleeding

Minor
21 (18.1%)
Major
63 (54.3%)
Life-threatening or disabling
32 (27.6%)

Independent factors associated with LBEs

Periprocedural (<30 days post-TAVR) major bleeding and antiplatelet + anticoagulation therapy at discharge
P ≤ 0.02 for all

All-cause mortality after TAVR (independent predictor)

LBE independent predictor of all-cause mortality, HR 1.39 (95% CI 1.05-1.83)
P = 0.020

Original publication

Late Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention in the Workup Pre-TAVR. JACC Cardiovasc Interv. Published 11 September 2023. doi:10.1016/j.jcin.2023.06.037

Summarised from the published abstract; every number is checked against it